Aluminium adjuvants used in vaccines

Djurisic, Snezana; Jakobsen, Janus Christian; Petersen, Susanne; Kenfelt, Mette; Klingenberg, Sarah Louise; Gluud, Christian

doi:10.1002/14651858.cd013086

Cited by 11 publications

(13 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, subunit vaccines have limited immunogenicity, mostly because they lack natural adjuvants [7]. Therefore, currently, almost every vaccine contains adjuvants, which enhance and prolong the immune response [8].…”

Section: Introductionmentioning

confidence: 99%

Inflammasomes as Targets for Adjuvants

et al. 2020

View full text Add to dashboard Cite

Inflammasomes are an essential part of the innate immune system. They are necessary for the development of a healthy immune response against infectious diseases. Inflammasome activation leads to the secretion of pro-inflammatory cytokines such as IL-1β and IL-18, which stimulate the adaptive immune system. Inflammasomes activators can be used as adjuvants to provide and maintain the strength of the immune response. This review is focused on the mechanisms of action and the effects of adjuvants on inflammasomes. The therapeutic and prophylaxis significance of inflammasomes in infectious diseases is also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammasomes as Targets for Adjuvants

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For several decades, aluminium containing adjuvants (alums) have been very effective in human vaccination and were generally the only approved adjuvants by the United States Food and Drug Administration (FDA) due to its' excellent track record of safety, low cost and its application with variety of antigens. However, in the modern era of recombinant proteins and small peptides vaccination, alums are implicated with a number of limitations such as local reactions, zero effectiveness to some recombinant antigens, and poor augmentation ability to some cell-mediated immune responses, such as cytotoxic T-cell responses [5]. Hence, there are several ongoing studies to investigate other effective adjuvants such as biodegradable polymeric particle technology.…”

Section: Introductionmentioning

confidence: 99%

Experimental and molecular predictions of the adjuvanticity of snail mucin on hepatitis B vaccine in albino mice

et al. 2021

View full text Add to dashboard Cite

Although aluminum-containing adjuvants are widely used in human vaccination due to their excellent safety profile, they exhibit low effectiveness with many recombinant antigens. This study investigated the adjuvanticity of snail mucin with recombinant Hepatitis B Vaccine (rHBsAg). Twenty-five (25) female mice distributed unbiasedly into 5 groups were used in the study and were administered different rHBsAg/Mucin formulation at 7 days intervals. Blood samples were collected a day following the administration for analysis. The results of liver function and body weight analysis were indications that snail mucin had no adverse effect on the mice. The treatment group (administer mucin and rHBsAg) showed significantly (P<0.05) higher mean titres of anti-HBsAg antibodies when compared with the negative controls and the positive control administered with two doses of rHBsAg after the boost doses (day 28). Furthermore, a comparable immune response to positive control administered with three doses rHBaAG was recorded. In silico prediction, studies of the protein-protein interaction of a homology modelled snail mucus protein and HBsAg gave an indication of enhanced HBV antigen-antibody interaction. Therefore, this study has shown that snail mucin possesses some adjuvant properties and enhances immune response towards rHBsAg vaccine. However, there is a need for further molecular dynamics studies to understand its mechanism of action.

show abstract

“…Adjuvants are substances added to vaccines to improve the immune response of pure antigens, which may not stimulate adequate immune response on their own [4] For several decades, aluminium containing adjuvants (alums) have been very effective in human vaccination and were generally the only approved adjuvants by the United States Food and Drug Administration (FDA) due to its' excellent track record of safety, low cost and its application with variety of antigens. However, in the modern era of recombinant proteins and small peptides vaccination, alums are implicated with a number of limitations such as local reactions, zero effectiveness to some recombinant antigens, and poor augmentation ability to some cell-mediated immune responses, such as cytotoxic T-cell responses [5]. Hence, there are several ongoing studies to investigate other effective adjuvants such as biodegradable polymeric particle technology.…”

Section: Introductionmentioning

confidence: 99%

Experimental and Molecular Predictions of the Adjuvanticity of Snail Mucin on Hepatitis B Vaccine in Albino Mice

Joshua

Nwauzor

Odimegwu

et al. 2021

Preprint

View full text Add to dashboard Cite

Although aluminum-containing adjuvants are widely used in human vaccination due to their excellent safety profile, they exhibit low effectiveness with many recombinant antigens. This study investigated the adjuvanticity of snail mucin with recombinant Hepatitis B Vaccine (rHBsAg). Twenty-five (25) female mice distributed unbiasedly into 5 groups were used in the study and were administered different rHBsAg/Mucin formulation at 7 days intervals. Blood samples were collected a day following the administration for analysis. The results of liver function and body weight analysis were indications that snail mucin had no adverse effect on the mice. The treatment group (administer mucin and rHBsAg) showed significantly (P<0.05) higher mean titres of anti-HBsAg antibodies when compared with the negative controls and the positive control administered with two doses of rHBsAg. Furthermore, a comparable immune response to positive control administered with three doses rHBaAG was recorded. In silico prediction, studies of the protein-protein interaction of a homology modelled snail mucus protein and HBsAg gave an indication of enhanced HBV antigen-antibody interaction. Therefore, this study has shown that snail mucin possesses some adjuvant properties and enhances immune response towards rHBsAg vaccine. However, there is a need for further molecular dynamics studies to understand its mechanism of action.

show abstract

Aluminium adjuvants used in vaccines

Cited by 11 publications

References 93 publications

Inflammasomes as Targets for Adjuvants

Inflammasomes as Targets for Adjuvants

Experimental and molecular predictions of the adjuvanticity of snail mucin on hepatitis B vaccine in albino mice

Experimental and Molecular Predictions of the Adjuvanticity of Snail Mucin on Hepatitis B Vaccine in Albino Mice

Contact Info

Product

Resources

About